The Protocol Specific Research Support (PSRS) funding of the CCSG supports research personnel dedicated to the development, implementation, conduct, and completion of high priority, innovative investigator-initiated phase I clinical trials. This resource is of high priority to the Cancer Center given the renewed and strong commitment to translational research and early phase clinical studies. In particular, this funding mechanism is critical for the YCC to fulfill its mission of translating the most exciting discoveries and science coming from YCC research labs into the clinical setting. As such, these types of translational clinical studies are complex in nature and design, as they incorporate important correlative, biologic, pharmacokinetic, and pharmacodynamic studies. While the YCC PSRS has always supported investigatorinitiated studies, the PSRS anticipates a significant increase in investigator-initiated clinical trials during the next funding period with an increased need to support these investigators. The main goals of the PSRS are to (1) provide nursing and data management support for investigator-initiated pilot phase I clinical studies, (2) provide assistance to investigators in the development and start-up of innovative studies, (3) provide assistance in eligibility determination and recruitment of patients for these clinical studies, (4) ensure the safe conduct of clinical research by monitoring patients, (5) provide source documentation for timely and complete entry in the PRS, (6) report study results, and (7) ensure compliance with federal and regulatory mandates. This effort .will require research nurses and data managers who have experience to ensure the safety, integrity, and success of these important studies. The continuity of staffing is essential to the success of studies presently on-going and to those that will be developed in the next funding period. The PSR interacts closely with the other key elements of the YCC clinical trials program, which include the Clinical Research Services (CRS) and the Protocol Review and Monitoring System (PRMS), and working together in an integrated, highly coordinated manner, these 3 elements serve as the cornerstone for the YCC clinical investigations program, The PSRS also interacts closely with the YCC Clinical/Translational Research Programs, including Developmental Therapeutics (DT), Radiobiology &Radiotherapy (R&R), and Immunology &Immunotherapy (l&l). The SPORE in Skin Cancer with a special focus on melanoma showcases the highly interdisciplinary, interprogrammatic collaborations between the DT, l&l, and Cancer Prevention and Control Programs and highlights the focus on developing innovative clinical studies that stem directly from YCC pre-clinical laboratory investigation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-31
Application #
7916708
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
31
Fiscal Year
2009
Total Cost
$101,750
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083

Showing the most recent 10 out of 675 publications